BioGaia AB (publ) (BIOG-B.ST)
SEK 101.1
(2.17%)
SEK 101.1
(2.17%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 8.8 Million SEK | -56.19% |
| 2022 | 20.08 Million SEK | 93.15% |
| 2021 | 10.4 Million SEK | 16.85% |
| 2020 | 8.9 Million SEK | 0.0% |
| 2019 | 8.9 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | -100.0% |
| 2010 | 1.02 Million SEK | 54.97% |
| 2009 | 664 Thousand SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| 2007 | - SEK | 0.0% |
| 2006 | - SEK | -100.0% |
| 2005 | 2.98 Million SEK | 0.0% |
| 2004 | - SEK | -100.0% |
| 2003 | 7.85 Million SEK | 0.0% |
| 2002 | 7.85 Million SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | - SEK | 0.0% |
| 2024 Q1 | - SEK | -100.0% |
| 2024 Q2 | - SEK | 0.0% |
| 2023 FY | 8.8 Million SEK | -56.19% |
| 2023 Q4 | 8.8 Million SEK | 0.0% |
| 2023 Q1 | - SEK | -100.0% |
| 2023 Q3 | - SEK | 0.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2022 Q3 | - SEK | 0.0% |
| 2022 Q4 | 20.08 Million SEK | 0.0% |
| 2022 FY | 20.08 Million SEK | 93.15% |
| 2022 Q1 | 106.3 Million SEK | 922.19% |
| 2022 Q2 | - SEK | -100.0% |
| 2021 Q1 | 16.63 Million SEK | 86.88% |
| 2021 FY | 10.4 Million SEK | 16.85% |
| 2021 Q2 | 16.03 Million SEK | -3.61% |
| 2021 Q4 | 10.4 Million SEK | -23.54% |
| 2021 Q3 | 13.6 Million SEK | -15.16% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q4 | 8.9 Million SEK | 0.0% |
| 2020 Q1 | - SEK | -100.0% |
| 2020 FY | 8.9 Million SEK | 0.0% |
| 2019 Q1 | 16.25 Million SEK | 0.0% |
| 2019 FY | 8.9 Million SEK | 0.0% |
| 2019 Q4 | 8.9 Million SEK | -26.98% |
| 2019 Q3 | 12.18 Million SEK | -12.37% |
| 2019 Q2 | 13.9 Million SEK | -14.44% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q1 | 117.93 Million SEK | 0.0% |
| 2018 Q2 | - SEK | -100.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2017 Q2 | 103.47 Million SEK | -1.87% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q4 | - SEK | -100.0% |
| 2017 Q3 | 104.27 Million SEK | 0.77% |
| 2017 Q1 | 105.44 Million SEK | 0.0% |
| 2016 Q4 | - SEK | -100.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q3 | 81.54 Million SEK | 4.16% |
| 2016 Q2 | 78.28 Million SEK | 9.57% |
| 2016 Q1 | 71.44 Million SEK | 0.0% |
| 2015 Q4 | - SEK | -100.0% |
| 2015 Q2 | 84.87 Million SEK | 2.01% |
| 2015 Q3 | 74.03 Million SEK | -12.77% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q1 | 83.2 Million SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q2 | 84.92 Million SEK | 15.53% |
| 2014 Q3 | 63.28 Million SEK | -25.48% |
| 2014 Q4 | - SEK | -100.0% |
| 2014 Q1 | 73.5 Million SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2013 Q1 | 39.07 Million SEK | 0.0% |
| 2013 Q4 | - SEK | -100.0% |
| 2013 Q3 | 39.03 Million SEK | 0.05% |
| 2013 Q2 | 39.01 Million SEK | -0.16% |
| 2012 Q1 | 128.65 Million SEK | 0.0% |
| 2012 Q2 | 114.42 Million SEK | -11.06% |
| 2012 Q4 | - SEK | -100.0% |
| 2012 Q3 | 84.11 Million SEK | -26.49% |
| 2012 FY | - SEK | 0.0% |
| 2011 FY | - SEK | -100.0% |
| 2011 Q2 | 44.27 Million SEK | 0.0% |
| 2011 Q1 | - SEK | -100.0% |
| 2011 Q4 | - SEK | -100.0% |
| 2011 Q3 | 43.68 Million SEK | -1.33% |
| 2010 Q2 | 34.15 Million SEK | 45.89% |
| 2010 Q3 | - SEK | -100.0% |
| 2010 FY | 1.02 Million SEK | 54.97% |
| 2010 Q4 | 1.02 Million SEK | 0.0% |
| 2010 Q1 | 23.41 Million SEK | 3425.6% |
| 2009 FY | 664 Thousand SEK | 0.0% |
| 2009 Q4 | 664 Thousand SEK | 0.0% |
| 2009 Q2 | 18.43 Million SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| 2007 FY | - SEK | 0.0% |
| 2006 FY | - SEK | -100.0% |
| 2005 FY | 2.98 Million SEK | 0.0% |
| 2004 FY | - SEK | -100.0% |
| 2003 FY | 7.85 Million SEK | 0.0% |
| 2002 FY | 7.85 Million SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| Enzymatica AB (publ) | 26.1 Million SEK | 66.287% |
| Enorama Pharma AB (publ) | 436 Thousand SEK | -1918.349% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | 18.93 Million SEK | 53.518% |
| Moberg Pharma AB (publ) | 4.73 Million SEK | -85.772% |
| Nanexa AB (publ) | 4.03 Million SEK | -118.254% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 473.8 Million SEK | 98.143% |
| Probi AB (publ) | 53.79 Million SEK | 83.642% |
| Swedencare AB (publ) | 1.65 Billion SEK | 99.469% |
| Swedish Orphan Biovitrum AB (publ) | 20.48 Billion SEK | 99.957% |
| Toleranzia AB | 850 Thousand SEK | -935.294% |
| Vivesto AB | 8.16 Million SEK | -7.738% |